REGENXBIO closes $370M upfront eye care collaboration with AbbVie for RGX-314 gene therapy

REGENXBIO Inc.

Upfront payment of $370M; potential for up to $1.38B in development, regulatory, and commercial milestones.
REGENXBIO and AbbVie to share equally in US profits; AbbVie to pay tiered royalties on ex-US net sales.
REGENXBIO responsible for ongoing trials; AbbVie leads global clinical development and commercialization.
REGENXBIO to lead manufacturing for clinical and US commercial supply; AbbVie for ex-US commercial supply.
Agreement covers RGX-314 for wet AMD, diabetic retinopathy, and other chronic retinal diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.